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Background: Approximately 80 000 Egyptians participate in Hajj pilgrimage annually. 
The purpose of this study was to estimate influenza virus and MERS- CoV prevalence 
among Egyptian pilgrims returning from Hajj.
Study: A cross- sectional survey among 3 364 returning Egyptian pilgrims from 2012 
to 2015 was conducted. Nasopharyngeal (NP) and oropharyngeal (OP) swabs were 
collected from all participants. Sputum specimens were collected from participants 
with respiratory symptoms and productive cough at the time of their interview. 
Specimens were tested for influenza viruses, and a convenience sample of NP/OP 
specimens was tested for MERS- CoV. Thirty percent of participants met the case defi-
nition for influenza- like illness (ILI), 14% tested positive for influenza viruses, and none 
tested positive for MERS- CoV. Self- reported influenza vaccination was 20%.
Conclusions: High prevalence of reported ILI during pilgrimage and confirmed influ-
enza virus on return from pilgrimage suggest a continued need for influenza preven-
tion strategies for Egyptian Hajj pilgrims. An evaluation of the Ministry of Health and 
Population’s current risk communication campaigns to increase influenza vaccine use 
among pilgrims may help identify strategies to improve vaccine coverage.
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The Hajj pilgrimage to Mecca, Saudi Arabia, is among the largest pil-
grimages in the world, with three million Muslims from over 180 coun-
tries participating every year, providing the potential for emerging 
epidemics.1 Acute respiratory tract infections are the most common 
diseases transmitted during Hajj, and influenza virus and rhinovirus are 
the most frequently detected respiratory viruses among pilgrims.2,3
In addition, there is public health concern about the risk of human 
infections from Middle East respiratory syndrome coronavirus (MERS- 
CoV) in Saudi Arabia. As of July 25, 2016, 1791 laboratory- confirmed 
cases of human infection with MERS- CoV from 26 countries were 
reported to the World Health Organization (WHO), including at least 
640 deaths (CFR 36%), with the majority of cases reported in Saudi 
Arabia.4 Direct contact with dromedary camels has been implicated 
as a risk factor for zoonotic MERS- CoV transmission, although the 
majority of MERS- CoV outbreaks have been linked to exposures in 
healthcare settings.5-7 Although sustained MERS- CoV transmission 
has not occurred to date, sporadic travel- related clusters have been 
documented, leading to concern about potential MERS- CoV dissem-
ination during Hajj.8
Approximately 80 000 Egyptians participate in Hajj pilgrim-
age annually.9 In the wake of the 2009 H1N1 influenza pandemic, 
the Egyptian Ministry of Health and Population (MOHP) required 
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pre- departure vaccination against influenza A(H1N1)pmd09 for all pil-
grims during the 2009 season.9 Since then, the MOHP has required 
seasonal influenza vaccination for all pilgrims as part of the Saudi visa 
application process. Although the requirement is not always enforced, 
seasonal influenza vaccine is available at local health offices for all 
Egyptian pilgrims throughout most of year. The MOHP has addition-
ally conducted an annual survey among pilgrims returning from Hajj 
to explore the risk of influenza virus transmission to the broader com-
munity. Following the emergence of MERS- CoV in Saudi Arabia, the 
MOHP expanded the survey to test for MERS- CoV.
2  | THE­STUDY
A cross- sectional survey was conducted at Cairo International Airport 
among Egyptians returning from Hajj during the week following the 
end of Hajj each year from 2012 to 2015 (Table 1). Cairo airport was 
selected for this survey as it is the main point of entry into Egypt for 
returning Hajj pilgrims.9 Cairo airport receives 7- 8 flights during work-
ing hours (9Am- 9 pm) from Saudi Arabia, accounting for approximately 
1500- 2000 pilgrims per day.
A team from the MOHP sought to enroll a convenience sample of 
approximately 10% of pilgrims from each flight returning from Hajj and 
congregating at the airport carousels, regardless of age, sex, and illness 
status. After providing verbal consent, participants were asked about 
demographic information, respiratory symptoms, and whether they re-
ceived vaccines as part of their Hajj visa application process. Both naso-
pharyngeal (NP) and oropharyngeal (OP) swabs were collected from all 
participants regardless of the presence of respiratory symptoms. Sputum 
specimens were collected from participants who presented with respi-
ratory symptoms and a productive cough at the time of their interview. 
Travelers who reported a history of subjective fever (a proxy for mea-
sured fever) and cough with symptom onset in the previous 10 days 
were categorized as having influenza- like illness (ILI).10 For minors, con-
sent and survey responses were provided by accompanying parents.
Samples were stored in viral transport media (VTM) on liquid nitro-
gen and transferred to the MOHP’s Central Public Health Laboratory 
on the day of collection. All NP/OP specimens were tested by real- 
time RT- PCR (rRT- PCR) for the presence of influenza A and B viruses. 
Specimens positive for influenza A were subsequently tested for influ-
enza A virus subtypes. Sputum specimens and a convenience sample 
of NP/OP specimens were tested for MERS- CoV according to WHO 
guidelines.11 The proportion of samples testing positive for influenza 
virus from participants was compared to those collected from ILI case- 
patients through the national surveillance system during the same 
time period.
TABLE  1 The distribution of Egyptian pilgrims surveyed by season according to gender, age group, presence of influenza- like illness (ILI), 

















Dates of Data 
Collection
3 Nov- 14 Nov 2012 22 Oct- 29 Oct 2013 11 Oct- 15 Oct 2014 29 Sept- 05 Oct 2015
Male 401 (48.7) 360 (48.7) 426 (51.5) 429 (44.1) 1616 (48.0)
Age groups
 <5 y 0 (0) 1 (0.1) 2 (0.2) 6 (0.6) 9 (0.3)
 5- <15 y 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 15- <50 y 215 (26.1) 255 (34.5) 222 (26.8) 217 (22.3) 909 (27.0)
 50- <65 y 446 (54.1) 369 (49.9) 475 (57.4) 577 (59.3) 1867 (55.5)
 65+ y 163 (19.8) 115 (15.5) 128 (15.5) 173 (17.8) 579 (17.2)
Reported symptoms 
consistent with ILI
319 (38.7) 326 (44.1) 195 (23.6) 183 (18.8) 1023 (30.4)
Vaccinated 162 (19.7) 69 (9.3) 244 (29.5) 189 (19.4) 664 (19.7)
Laboratory- confirmed 
influenza
145 (17.6) 105 (14.2)a 133 (16.1) 101 (10.4)b 484 (14.4)
 Influenza A (H1N1) 42 (5.1) 22 (3.0) 3 (0.4) 50 (5.1) 117 (3.5)
 Influenza A (H3N2) 54 (6.6) 38 (5.1) 60 (7.3) 35 (3.6) 187 (5.6)
 Influenza B 49 (6.0) 44 (6.0) 70 (8.5) 17 (1.8) 180 (5.4)
Tested for MERS- CoVc
 Sputum 25 (3.0) 60 (8.1) 100 (12.1) 79 (8.1) 264 (7.8)
 NP/OP 187 (22.7) 740 (100) 823 (99.5) 187 (19.2) 1937 (57.6)
aOne influenza A- positive specimen was not subtyped.
bOne specimen tested positive for both A(H1N1) and A(H3N2).
cAll MERS- CoV tests were negative. All sputum specimens were paired with NP/OP specimens.
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During the 2012- 2015 seasons, 3559 pilgrims were approached 
for participation; 3364 (94.5%) provided consent for participation and 
swab collection. An average of 135 pilgrims was interviewed daily for 
5- 8 days each year. The median age among participants was 56 years 
(range 0- 105), and 56% of participants were aged 50- 64 years (Table 1). 
Approximately half (1616 [48%]) of the participants were male. 
Surveyed pilgrims resided in 25 of the 27 governorates of Egypt, al-
though the majority were from Cairo, Giza, Menofia, and Qalyubia (774 
[23%], 423 [12.6%], 305 [9.1%], and 292 [8.7%] respectively) (Figure 1).
Self- reported influenza vaccination among participants was 
low across seasons, with an overall vaccination coverage of 19.7% 
throughout the study period. There was no difference in influenza 
vaccination coverage by age (median of 56 years among unvaccinated 
participants and 55 years among vaccinated participants, P=0.4) or by 
sex (19.5% females and 20.0% males, P=0.7).
Thirty percent of participants (1023/3364) reported symptoms con-
sistent with ILI during their travel. Approximately a fifth of those with 
ILI symptoms tested positive for influenza virus (217/1023; 21.2%). An 
additional 20.7% of participants with at least one reported respiratory 
symptom (242/1170) and 11.6% of participants without any of the 
four symptoms captured in the questionnaire (i.e., feverishness, cough, 
sore throat, and dyspnea) (141/1216) tested positive for influenza 
virus. There was no difference in the proportion of persons who were 
influenza virus positive by sex (14.7% females and 14.1% males, P- 
value=0.6) or by age (median of 55 years among influenza virus- positive 
participants and 56 years among influenza virus negative participants, 
P=0.9). The proportions of influenza virus- positive specimens among 
participants meeting the ILI case definition and among those collected 
through the national influenza surveillance system (hospitalized and 
outpatient ILI) were similar in 2012 and 2013 (2012: 26.0% vs 20.2% 
(P=0.1); 2013: 17.5% vs 17.3% (P=1.0), respectively), higher among 
participants in 2014 (28.2% among participants, 16.1% among those 
tested through the influenza surveillance system, P=0.008), and lower 
among participants in 2015 (12.0% among participants, 24.2% among 
those tested through the influenza surveillance system, P=0.006). 
MERS- CoV testing was conducted on NP/OP specimens for 1673 of 
3364 participants (49.7%) and on paired sputum and NP/OP specimens 
for 264 (7.8%) of participants; none tested positive for MERS- CoV.
3  | CONCLUSIONS
Thirty percent of surveyed Hajj pilgrims reported symptoms con-
sistent with ILI at some point during their pilgrimage and over 14% 
tested positive for seasonal influenza viruses on their return. The high 
prevalence of ILI during pilgrimage and confirmed influenza virus on 
the pilgrims’ return to Egypt suggests a continued need for influenza 
prevention strategies for Egyptian Hajj pilgrims. These findings are 
higher than those of prior surveys where influenza virus positivity 
was 1.3%- 7.8% among returning Hajj pilgrims regardless of clinical 
F IGURE  1 The geographical 
distribution for the governorate of origin 
of Egyptian pilgrims surveyed from 2012 
to 2015
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status.12, 13 Differences between our results and those of other stud-
ies might be due to subtle differences in sociodemographic charac-
teristics including age distribution and prior vaccination among those 
surveyed. Findings from this study may additionally be biased by the 
non- random selection of participants and recall bias.
While MERS- CoV was not detected in any respiratory swabs or 
sputum specimens collected from participants, no information regard-
ing health care or camel exposure was collected, limiting the interpre-
tation of these results. In future iterations, the MOHP could consider 
adding exposure questions to better understand the risk of MERS- CoV 
infection among Egyptians on Hajj. Additionally, upper respiratory tract 
specimens have been shown to yield significantly lower MERS- CoV 
genome loads than lower respiratory tract specimens (such as tracheal 
aspirates), which may have limited our ability to detect MERS- CoV.14
Despite the MOHP’s requirement of influenza vaccination for all 
Egyptian Hajj pilgrims, only 19.7% of participants reported receiving 
seasonal influenza vaccine prior to their pilgrimage. This figure may 
underestimate true influenza vaccine coverage, as interviewers only 
asked about vaccines received as part of Hajj travel preparations. 
Nevertheless, further health education through local media may help 
raise awareness about the value of influenza vaccination prior to depar-
ture for Hajj, especially among older age groups at high risk of influenza 
complications.15 An evaluation of the MOHP’s current risk communi-
cation campaigns to increase influenza vaccination use among pilgrims 
may help identify strategies to improve influenza vaccine coverage.
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